Brain monoamine oxidase a binding in major depressive disorder: Relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence

Archives of General Psychiatry

Volumn 66, Issue 12, 2009, Pages 1304-1312

  Meyer, Jeffrey H ^a   Wilson, Alan A ^a   Sagrati, Sandra ^a   Miler, Laura ^a   Rusjan, Pablo ^a   Bloomfield, Peter M ^a   Clark, Michael ^a   Sacher, Julia ^a   Voineskos, Aristotle N ^a   Houle, Sylvain ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CARBON 11; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BRAIN LEVEL; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BINDING; FEMALE; FOLLOW UP; HUMAN; ISOTOPE LABELING; MAJOR DEPRESSION; MALE; ONSET AGE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; RECURRENT DISEASE;

ADULT; BRAIN; BRAIN MAPPING; CARBON RADIOISOTOPES; DEPRESSIVE DISORDER, MAJOR; FEMALE; GYRUS CINGULI; HARMINE; HUMANS; MALE; MONOAMINE OXIDASE; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 73149086401     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2009.156     Document Type: Article

References (69)

1. Ustün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004;184:386-392.
2. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
3. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, Young T, Praschak-Rieder N, Wilson AA, Houle S. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006;63(11):1209-1216.
4. Bergström M, Westerberg G, Kihlberg T, Langstrom B. Synthesis of some 11C-labelled MAO-A inhibitors and their in vivo uptake kinetics in rhesus monkey brain. Nucl Med Biol. 1997;24(5):381-388.
5. Bergström M, Westerberg G, Langstrom B. 11C-harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies. Nucl Med Biol. 1997; 24(4):287-293.
6. Ginovart N, Meyer JH, Boovariwala A, Hussey D, Rabiner EA, Houle S, Wilson AA. Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain. J Cereb Blood Flow Metab. 2006;26(3):330-344.
7. Tweedie DJ, Burke MD. Metabolism of the beta-carbolines, harmine and harmol, by liver microsomes from phenobarbitone- or 3-methylcholanthrene-treated mice: identification and quantitation of two novel harmine metabolites. Drug Metab Dispos. 1987;15(1):74-81.
8. Haefely W, Burkard WP, Cesura AM, Kettler R, Lorez HP, Martin JR, Richards JG, Scherschlicht R, Da Prada M. Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology (Berl). 1992;106(suppl):S6-S14.
9. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7(4):295-309.
10. Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N, Goulding V, Kennedy J, Wilson AA. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry. 2004;61(12):1271-1279.
11. Meyer JH, Kruger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A, Minifie C, Houle S, Hussey D, Kennedy SH. Lower dopamine transporter binding potential in striatum during depression. Neuroreport. 2001;12(18):4121-4125.
12. Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, DaSilva JN, Wilson AA, Blak T, Eynan-Harvey R, Goulding VS, Houle S, Links P. Dysfunctional attitudes and 5-HT(2) receptors during depression and self-harm. Am J Psychiatry. 2003;160(1):90-99.
13. Meyer JH, McNeely HE, Sagrati S, Boovariwala A, Martin K, Verhoeff NP, Wilson AA, Houle S. Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am J Psychiatry. 2006;163(9):1594-1602.
14. Barton DA, Esler MD, Dawood T, Lambert EA, Haikerwal D, Brenchley C, Socratous F, Hastings J, Guo L, Wiesner G, Kaye DM, Bayles R, Schlaich MP, Lambert GW. Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy. Arch Gen Psychiatry. 2008;65(1):38-46.
15. Thase ME. Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry. 2003;64(suppl 13):18-25.
16. Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1990;47(12):1093-1099.
17. Leyton M, Young SN, Blier P, Ellenbogen MA, Palmour RM, Ghadirian AM, Benkelfat C. The effect of tryptophan depletion on mood in medication-free, former patients with major affective disorder. Neuropsychopharmacology. 1997;16 (4):294-297.
18. Smith KA, Clifford EM, Hockney RA, Clark DM, Cowen PJ. Effect of tryptophan depletion on mood in male and female volunteers: a pilot study. Hum Psychopharmacol. 1997;12(2):111-117.
19. Moreno FA, Gelenberg AJ, Heninger GR, Potter RL, McKnight KM, Allen J, Phillips AP, Delgado PL. Tryptophan depletion and depressive vulnerability. Biol Psychiatry. 1999;46(4):498-505.
20. Moreno FA, Heninger GR, McGahuey CA, Delgado PL. Tryptophan depletion and risk of depression relapse: a prospective study of tryptophan depletion as a potential predictor of depressive episodes. Biol Psychiatry. 2000;48(4):327-329.
21. Neumeister A, Nugent AC, Waldeck T, Geraci M, Schwarz M, Bonne O, Bain EE, Luckenbaugh DA, Herscovitch P, Charney DS, Drevets WC. Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry. 2004;61(8):765-773.
22. Berman RM, Narasimhan M, Miller HL, Anand A, Cappiello A, Oren DA, Heninger GR, Charney DS. Transient depressive relapse induced by catecholamine depletion: potential phenotypic vulnerability marker? Arch Gen Psychiatry. 1999;56(5):395-403.
23. Hasler G, Fromm S, Carlson PJ, Luckenbaugh DA, Waldeck T, Geraci M, Roiser JP, Neumeister A, Meyers N, Charney DS, Drevets WC. Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry. 2008;65(5):521-531.
24. Freis ED. Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N Engl J Med. 1954;251(25):1006- 1008.
25. Burrell RH. Depression associated with reserpine therapy. N Z Med J. 1956;55(307):228-231.
26. Liotti M, Mayberg HS, McGinnis S, Brannan SL, Jerabek P. Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression. Am J Psychiatry. 2002;159(11):1830- 1840.
27. Krüger S, Alda M, Young LT, Goldapple K, Parikh S, Mayberg HS. Risk and resilience markers in bipolar disorder: brain responses to emotional challenge in bipolar patients and their healthy siblings. Am J Psychiatry. 2006;163(2):257-264.
28. Knutson B, Taylor J, Kaufman M, Peterson R, Glover G. Distributed neural representation of expected value. J Neurosci. 2005;25(19):4806-4812.
29. Tom SM, Fox CR, Trepel C, Poldrack RA. The neural basis of loss aversion in decision-making under risk. Science. 2007;315(5811):515-518.
30. Sharot T, Riccardi AM, Raio CM, Phelps EA. Neural mechanisms mediating optimism bias. Nature. 2007;450(7166):102-105.
31. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, Alexoff D, Mac-Gregor RR, Schlyer DJ, Zezulkova I, Wolf AP. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A. 1996;93(24):14065-14069.
32. First M, Spitzer R, Williams J, Gibbon M. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), version 2. New York, NY: Biometrics Research; 1995.
33. Blais MA, Norman DK. A psychometric evaluation of the DSM-IV personality disorder criteria. J Pers Disord. 1997;11(2):168-176.
34. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62.
35. Knoess C, Rist J, Michel C, Burbar Z, Eriksson L, Panin V, Byars L, Lenox M, Wienhard K, Heiss W-D, Nutt R. Evaluation of single photon transmission for the HRRT. IEEE Nucl Sci Symp Conf Rec. 2003;3:1936-1940.
36. Karp JS, Muehllehner G, Lewitt R. Constrained Fourier space method for compensation of missing data in emission computed tomography. IEEE Trans Med Imaging. 1988;7(1):21-25.
37. Watson C, Newport D, Casey M, deKemp R, Beanlands R, Schmand M. Evaluation of simulation-base scatter correction for 3D PET cardiac imaging. IEEE Trans Nucl Sci. 1996;44:90-97.
38. Defrise M, Kinahan P, Townsend D, Michel C, Sibomana M, Newport D. Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imaging. 1997;16(2):145-158.
39. Studholme C, Hill D, Hawkes D. An overlap invariant entropy measure of 3D medical image alignment. Pattern Recognit. 1999;32(1):71-86.
40. Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Hum Brain Mapp. 1999;7(4):254-266.
41. Ashburner J, Neelin P, Collins DL, Evans A, Friston K. Incorporating prior knowledge into image registration. Neuroimage. 1997;6(4):344-352.
42. Rusjan P, Mamo D, Ginovart N, Hussey D, Vitcu I, Yasuno F, Tetsuya S, Houle S, Kapur S. An automated method for the extraction of regional data from PET images. Psychiatry Res. 2006;147(1):79-89.
43. Ashburner J, Friston K. Multimodal image coregistration and partitioning - a unified framework. Neuroimage. 1997;6(3):209-217.
44. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Huang Y, Simpson N, Ngo K, Van Heertum R, Laruelle M. Imaging human mesolimbic dopamine transmission with positron emission tomography, I: accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab. 2001;21(9):1034-1057.
45. Bel N, Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse. 1993;15(3):243-245.
46. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340(2-3):249-258.
47. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997;283(3):1305-1322.
48. Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, Wilson AA, Rafi-Tari S, Mayberg HS, Kennedy SH. The effect of paroxetine upon 5-HT2A receptors in depression: an [18F] setoperone PET imaging study. Am J Psychiatry. 2001;158(1):78-85.
49. Taylor BP, Bruder GE, Stewart JW, McGrath PJ, Halperin J, Ehrlichman H, Quitkin FM. Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am J Psychiatry. 2006;163(1):73-78.
50. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry. 2001;158(11):1843-1849.
51. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161(5):826-835.
52. Meyer JH. Applying neuroimaging ligands to study major depressive disorder. Semin Nucl Med. 2008;38(4):287-304.
53. Biver F, Wikler D, Lotstra F, Damhaut P, Goldman S, Mendlewicz J. Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex. Br J Psychiatry. 1997;171:444-448.
54. Mintun MA, Sheline YI, Moerlein SM, Vlassenko AG, Huang Y, Snyder AZ. Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biol Psychiatry. 2004;55(3):217-224.
55. Yatham LN, Liddle PF, Shiah IS, Scarrow G, Lam RW, Adam MJ, Zis AP, Ruth TJ. Brain serotonin2 receptors in major depression: a positron emission tomography study. Arch Gen Psychiatry. 2000;57(9):850-858.
56. Stockmeier CA. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J Psychiatr Res. 2003;37(5):357-373.
57. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653-661.
58. Simons AD, Murphy GE, Levine JL, Wetzel RD. Cognitive therapy and pharmacotherapy for depression: sustained improvement over one year. Arch Gen Psychiatry. 1986;43(1):43-48.
59. Bhagwagar Z, Hinz R, Taylor M, Fancy S, Cowen P, Grasby P. Increased 5-HT (2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. Am J Psychiatry. 2006;163(9):1580-1587.
60. Stockmeier CA, Kellar KJ. In vivo regulation of the serotonin-2 receptor in rat brain. Life Sci. 1986;38(2):117-127.
61. Roth BL, McLean S, Zhu X, Chuang D. Characterization of two [3H]ketanserin recognition sites in rat striatum. J Neurochem. 1987;49(6):1833-1838.
62. Todd KG, McManus DJ, Baker GB. Chronic administration of the antidepressants phenelzine, desipramine, clomipramine, or maprotiline decreases binding to 5-hydroxytryptamine2A receptors without affecting benzodiazepine binding sites in rat brain. Cell Mol Neurobiol. 1995;15(3):361-370.
63. O'Regan D, Kwok RP, Yu PH, Bailey BA, Greenshaw AJ, Boulton AA. A behavioural and neurochemical analysis of chronic and selective monoamine oxidase inhibition. Psychopharmacology (Berl). 1987;92(1):42-47.
64. Smith KA, Fairburn CG, Cowen PJ. Relapse of depression after rapid depletion of tryptophan. Lancet. 1997;349(9056):915-919.
65. Ruhé HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry. 2007;12(4):331-359.
66. Mendels J, Frazer A. Brain biogenic amine depletion and mood. Arch Gen Psychiatry. 1974;30(4):447-451.
67. Pinsonneault JK, Papp AC, Sadee W. Allelic mRNA expression of X-linked monoamine oxidase a (MAOA) in human brain: dissection of epigenetic and genetic factors. Hum Mol Genet. 2006;15(17):2636-2649.
68. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behaviour. Annu Rev Neurosci. 1999;22:197-217.
69. Shao L, Martin MV, Watson SJ, Schatzberg A, Akil H, Myers RM, Jones EG, Bunney WE, Vawter MP. Mitochondrial involvement in psychiatric disorders. Ann Med. 2008;40(4):281-295.